argenx SE American Depositary Shares

ARGX

...

ARGX: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Show ARGX Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of ARGX by members of U.S. Congress

Politician	Type	Traded
Daniel Goldman House / D	Sale $1,001 - $15,000	Jul. 10, 2023

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ARGX's directors and management

No recent Insider Trading for this ticker

Insider Trading Dashboard

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on ARGX's company Twitter account

WallStreetBets

Number of mentions of ARGX in WallStreetBets Daily Discussion

ARGX News

Recent insights relating to ARGX

CNBC Recommendations

Recent picks made for ARGX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ARGX

Corporate Flights

Flights by private jets registered to ARGX